Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Five Big Legal Stories From 2022

Teva, Sandoz And Viatris All Featured Prominently In 2022’s Stand Out Cases

Jan 27 2023

• By Dean Rudge

Gavel — • Source: Shutterstock: New Africa

Related Content

Long-Awaited Nationwide Opioid Settlement To Move Forward For Teva

Jan 12 2023

Alvotech And Teva File US Stelara Rival Ahead Of 2023 Expiry

Jan 06 2023

Skinny-Label Saga Hangs In Balance As Supreme Court Seeks Input

Oct 18 2022

Teva Seeks To Draw A Line Under Opioids Litigation With Final US Settlement

Nov 23 2022

As US Court Chops Another Symbicort Patent, Will Viatris Make Its Move?

Nov 11 2022

Teva’s New York Opioid Liability Climbs To $523m With Settlement Deal

Nov 04 2022

Amgen Sued On US Stelara Biosimilar After Providing May 2023 Intent

Dec 01 2022

Infringement Order Blocks Viatris’ US Symbicort Rival Until July 2023

Dec 20 2022

Teva Introduces First Eliquis Rival In UK

May 31 2022

Teva Inks $4.35bn Nationwide US Opioids Settlement Agreement

Jul 27 2022

Appeals Court Rehearing Rejected In Teva-GSK Skinny-Label Saga

Feb 14 2022

Apotex Debuts Eliquis Rival In Canada

Jun 22 2022

ANDA Filers Lose Again On Eliquis Patents With Monopoly Set For 2028

Sep 08 2021

Additional Topics

Europe Legal Issues Intellectual Property BioPharmaceutical

More from Legal & IP

More from Generics Bulletin

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window